Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women

Journal of Infectious Diseases

Volumn 212, Issue 6, 2015, Pages 924-933

  Lo Re, Vincent ^a,c,d,e   Lynn, Kenneth ^a,c   Stumm, Emily R ^a,c   Long, Jin ^f   Nezamzadeh, Melissa S ^d   Baker, Joshua F ^b   Hoofnagle, Andrew N ^h   Kapalko, Angela J ^g   Mounzer, Karam ^g   Zemel, Babette S ^e   Tebas, Pablo ^a,c   Kostman, Jay R ^a,c   Leonard, Mary B ^d,i  

^a Department of Medicine   (United States)

^b Division of Rheumatology   (United States)

^c AIDS Research   (United States)

^d Center for Clinical Epidemiology and Biostatistics   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g Philadelphia Fight   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

Author keywords

bone; coinfection; hepatitis C virus; HIV; peripheral quantitative computed tomography

Indexed keywords

25 HYDROXYVITAMIN D; ANTIRETROVIRUS AGENT; CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; VIRUS RNA; VITAMIN D; CYTOKINE;

ADULT; BODY COMPOSITION; BONE DENSITY; BONE DISEASE; BONE FRAGILITY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOSTEAL CIRCUMFERENCE; FEMALE; HEPATITIS C; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MIXED INFECTION; MUSCULOSKELETAL SYSTEM PARAMETERS; OSTEOLYSIS; PERIOSTEAL CIRCUMFERENCE; PRIORITY JOURNAL; RACE DIFFERENCE; TIBIA; TRABECULAR BONE; VIRUS LOAD; VITAMIN D METABOLISM; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; OSTEOPOROSIS; PATHOLOGY; VIROLOGY;

ADULT; BONE DENSITY; COINFECTION; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MIDDLE AGED; OSTEOPOROSIS; VITAMIN D;

EID: 84940748638     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv147     Document Type: Conference Paper

References (54)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-74.
2. Brown TT, Chen Y, Currier JS, et al. Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapynaive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2013; 63:323-30.
3. Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology 2001; 33:301-7.
4. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125:941-66.
5. van Vonderen MG, Lips P, van Agtmael MA, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23:1367-76.
6. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-72.
7. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavirlamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-801.
8. Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011; 6:e17217.
9. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-8.
10. Lo Re V 3rd, Volk J, Newcomb CW, et al. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology 2012; 56:1688-98.
11. Anastos K, Lu D, Shi O, et al. The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther 2007; 12:1049-58.
12. Lo Re V 3rd, Guaraldi G, Leonard MB, et al. Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS 2009; 23:2191-8.
13. Yin MT, McMahon DJ, Ferris DC, et al. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2010; 95:620-9.
14. Lawson-Ayayi S, Cazanave C, Kpozehouen A, et al. Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort. J Acquir Immune Defic Syndr 2013; 62:430-5.
15. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937-46.
16. Gilbert L, He X, Farmer P, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 2002; 277:2695-701.
17. Radeff JM, Nagy Z, Stern PH. Involvement of PKC-beta in PTH, TNF-alpha, and IL-1 beta effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption. Exp Cell Res 2001; 268:179-88.
18. Kontulainen SA, Johnston JD, Liu D, Leung C, Oxland TR, McKay HA. Strength indices from pQCT imaging predict up to 85% of variance in bone failure properties at tibial epiphysis and diaphysis. J Musculoskelet Neuronal Interact 2008; 8:401-9.
19. Liu D, Manske SL, Kontulainen SA, et al. Tibial geometry is associated with failure load ex vivo: a MRI, pQCT and DXA study. Osteoporos Int 2007; 18:991-7.
20. Dubner SE, Shults J, Baldassano RN, et al. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology 2009; 136:123-30.
21. Tsampalieros A, Lam CK, Spencer JC, et al. Long-term inflammation and glucocorticoid therapy impair skeletal modeling during growth in childhood Crohn disease. J Clin Endocrinol Metab 2013; 98: 3438-45.
22. Aeberli D, Eser P, Bonel H, et al. Reduced trabecular bone mineral density and cortical thickness accompanied by increased outer bone circumference in metacarpal bone of rheumatoid arthritis patients: a cross-sectional study. Arthritis Res Ther 2010; 12:R119.
23. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
24. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-7.
25. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis 2006; 42:108-14.
26. Hofmann WP, Kronenberger B, Bojunga J, et al. Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy. J Viral Hepat 2008; 15:790-6.
27. Baker JF, Davis M, Alexander R, et al. Associations between body composition and bone density and structure in men and women across the adult age spectrum. Bone 2013; 53:34-41.
28. Isaacson JH, Butler R, Zacharek M, Tzelepis A. Screening with the Alcohol use Disorders Identification Test (AUDIT) in an inner-city population. J Gen Intern Med 1994; 9:550-3.
29. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998; 158:1789-95.
30. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002; 156: 871-81.
31. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32(Suppl 9):S498-504.
32. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C: the METAVIR Cooperative Study Group. Hepatology 1996; 24:289-93.
33. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3:8.
34. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51:1867-73.
35. The International Society for Clinical Densitometry. 2007 Official Positions and Pediatric Official Positions of the International Society for Clinical Densitometry. http://www.iscd.org/wp-content/uploads/2012/10/ISCD2007OfficialPositions-Combined-AdultandPediatric.pdf. Accessed 23 April 2014.
36. Leonard MB, Shults J, Elliott DM, Stallings VA, Zemel BS. Interpretation of whole body dual energy x-ray absorptiometry measures in children: comparison with peripheral quantitative computed tomography. Bone 2004; 34:1044-52.
37. Kelly TL, Wilson KE, Heymsfield SB. Dual energy x-Ray absorptiometry body composition reference values from NHANES. PLoS One 2009; 4:e7038.
38. Serum-calcium [editorial]. Lancet 1979; 1:858-9.
39. Hoofnagle AN, Laha TJ, Donaldson TF. A rubber transfer gasket to improve the throughput of liquid-liquid extraction in 96-well plates: application to vitamin D testing. J Chromatogr B Analyt 2010; 878:1639-42.
40. Strathmann FG, Laha TJ, Hoofnagle AN. Quantification of 1alpha,25-dihydroxy vitamin D by immunoextraction and liquid chromatography-tandem mass spectrometry. Clin Chem 2011; 57:1279-85.
41. Laha TJ, Strathmann FG, Wang Z, de Boer IH, Thummel KE, Hoofnagle AN. Characterizing antibody cross-reactivity for immunoaffinity purification of analytes prior to multiplexed liquid chromatography-tandem mass spectrometry. Clin Chem 2012; 58:1711-6.
42. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-81.
43. Cole TJ. The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990; 44:45-60.
44. Tsampalieros A, Kalkwarf HJ, Wetzsteon RJ, et al. Changes in bone structure and the muscle-bone unit in children with chronic kidney disease. Kidney Int 2013; 83:495-502.
45. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141:3956-64.
46. Lee SE, Chung WJ, Kwak HB, et al. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 2001; 276:49343-9.
47. El-Maouche D, Mehta SH, Sutcliffe C, et al. Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection. J Hepatol 2011; 55:770-6.
48. Walker Harris V, Sutcliffe CG, Araujo AB, et al. Hip bone geometry in HIV/HCV-co-infected men and healthy controls. Osteoporos Int 2012; 23:1779-87.
49. Calmy A, Chevalley T, Delhumeau C, et al. Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal women. Osteoporos Int 2013; 24:1843-52.
50. Yin MT, Lund E, Shah J, et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life. AIDS 2014; 28:345-53.
51. Zhao LJ, Liu YJ, Liu PY, et al. Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 2007; 92:1640-6.
52. Rosenthall L, Falutz J Bone mineral and soft-tissue changes in AIDSassociated lipoatrophy. J Bone Miner Metab 2005; 23:53-7.
53. Dube MP, Parker RA, Mulligan K, et al. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis 2007; 45:120-6.
54. Shikuma CM, Zackin R, Sattler F, et al. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis 2004; 39:1223-30.